Foley Represents Verona Pharma in $10B Acquisition by Merck

Foley & Lardner LLP acted as U.S. intellectual property counsel for UK-based Verona Pharma, a biopharmaceutical company focused on respiratory diseases, in its approximately $10 billion acquisition by Merck & Co. Inc. (Merck). The acquisition gives Merck access to Ohtuvayre, a newly approved inhaled treatment for chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre is […]